Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids

Diabetologia

Volumn 56, Issue 10, 2013, Pages 2266-2274

  Orešič, Matej ^a   Hyötyläinen, Tuulia ^a   Kotronen, Anna ^b   Gopalacharyulu, Peddinti ^a   Nygren, Heli ^a   Arola, Johanna ^b   Castillo, Sandra ^a   Mattila, Ismo ^a   Hakkarainen, Antti ^b   Borra, Ronald J H ^c,d   Honka, Miikka Juhani ^c   Verrijken, An ^e   Francque, Sven ^e   Iozzo, Patricia ^c,f   Leivonen, Marja ^g   Jaser, Nabil ^g   Juuti, Anne ^g   Sørensen, Thorkild I A ^h   Nuutila, Pirjo ^c   Van Gaal, Luc ^d   Yki Järvinen, Hannele ^b   more..

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h The Capital Region   (Denmark)

Author keywords

Lipidomics; Mass spectrometry; Non alcoholic fatty liver disease

Indexed keywords

BIOLOGICAL MARKER; LIPID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; FAT CONTENT; FEMALE; HUMAN; LIPID ANALYSIS; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NONALCOHOLIC FATTY LIVER; PHOSPHOLIPID BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY; WEIGHT REDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FATTY LIVER; FEMALE; HUMANS; LIPIDS; LIVER; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84890116926     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2981-2     Document Type: Article

References (46)

1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231
2. Targher G (2007) Non-alcoholic fatty liver disease as a determinant of cardiovascular disease. Atherosclerosis 190:18-19, author reply 20-11
3. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK (2009) NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104:861-867
4. Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27-38
5. Van Gaal LF, Mertens IL, de Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875-880
6. Agopian VG, Kaldas FM, Hong JC et al (2012) Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 256:624-633
7. Siegelman ES, Rosen MA (2001) Imaging of hepatic steatosis. Semin Liver Dis 21:71-80
8. Browning JD, Szczepaniak LS, Dobbins R et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395
9. Machado MV, Cortez-Pinto H (2013) Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58:1007-1019
10. Kotronen A, Peltonen M, Hakkarainen A et al (2009) Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137:865-872
11. Kotronen A, Seppanen-Laakso T, Westerbacka J et al (2009) Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58:203-208
12. Westerbacka J, Kotronen A, Fielding BA et al (2010) Splanchnic balance of free fatty acids, endocannabinoids and lipids in subjects with NAFLD. Gastroenterology 139:1961-1971
13. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343-1351
14. Aarsland A, Wolfe RR (1998) Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. J Lipid Res 39:1280-1286
15. Nygren H, Seppanen-Laakso T, Castillo S, Hyotylainen T, Oresic M (2011) Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. Methods Mol Biol 708:247-257
16. Francque S, Verrijken A, Mertens I et al (2011) Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. Int J Obes (Lond) 35:270-278
17. Kotronen A, Vehkavaara S, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H (2007) Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293:E1709-E1715
18. Ryysy L, Hakkinen AM, Goto T et al (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758
19. Machann J, Thamer C, Schnoedt B et al (2006) Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. Magn Reson Med 55:913-917
20. Sutinen J, Hakkinen AM, Westerbacka J et al (2002) Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16:2183-2193
21. Szczepaniak LS, Nurenberg P, Leonard D et al (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462-E468
22. Pluskal T, Castillo S, Villar-Briones A, Oresic M (2010) MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinforma 11:395
23. Fraley C, Raftery AE (2007) Model-based methods of classification: using the mclust software in chemometrics. J Stat Soft 18:1-13
24. Mitchell M, Forrest S (1994) Genetic algorithms and artificial life. Artificial Life 1:267-289
25. Maes P (1993) Modeling adaptive autonomous agents. Artificial Life 1:135-162
26. McCullagh P, Nelder JA (1989) Generalized linear models. Chapman & Hall/CRC, Boca Raton
27. Hoerl AE, Kennard RW (1970) Ridge regression: biased estimation for nonorthogonal problems. Technometrics 12:55-67
28. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837-845
29. Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma 12:77
30. Guha IN, Parkes J, Roderick P et al (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47:455-460
31. Kotronen A, Velagapudi VR, Yetukuri L et al (2009) Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52:684-690
32. Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G (2009) Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 50:574-585
33. Yetukuri L, Söderlund S, Koivuniemi A et al (2010) Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res 51:2341-2351
34. Bergholm R, Sevastianova K, Santos A et al (2012) CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. Int J Obes (Lond). doi: 10.1038/ijo.2012.1116
35. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S (2008) Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134:424-431
36. Adiels M, Westerbacka J, Soro-Paavonen A et al (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50:2356-2365
37. Sevastianova K, Santos A, Kotronen A et al (2012) Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 96:727-734
38. Rhee EP, Cheng S, Larson MG et al (2011) Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 121:1402-1411
39. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM et al (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028
40. Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755-765
41. Poynard T, Ratziu V, Naveau S et al (2005) The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 4:10
42. Bedogni G, Bellentani S, Miglioli L et al (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33
43. Xia MF, Yan HM, He WY et al (2012) Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring) 20:444-452
44. Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V (2011) Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Gastroenterol Clin Biol 35:23-28
45. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442-451
46. Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675-1685